ArticleArchives of toxicology2026
In vitro toxicokinetics and metabolic profiling of methoxycathinones and methylthiocathinones using human liver systems and hyphenated mass spectrometry.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Human serum-supplemented cell culture conditions improve xenobiotic metabolism in hepatoma cell lines HepG2 and Huh7.Archives of toxicology · 2026Article
- Toxicokinetic Studies of the Two Stimulants M-ALPHA andMetabolites · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ring-substituted synthetic cathinones represent a major subgroup within new psychoactive substances. This study investigated the in vitro toxicokinetics of the three 4-methoxy-substituted representatives 4MeO-NE-BP (4'-methoxy-N-ethylbutyrophenone), 4MeO-αP-BP (4'-methoxy-α-pyrrolidinobutyrophenone), and 4MeO-αP-VP (4'-methoxy-α-pyrrolidinovalerophenone) and the three related novel 4-methylthio analogs 4MeS-NE-BP (4'-methylthio-N-ethylbutyrophenone), 4MeS-αP-BP (4'-methylthio-α-pyrrolidinobutyrophenone), and 4MeS-αMor-PrP (4'-methylthio-2-morpholinopropiophenone). This included plasma protein binding (PPB), phase I and phase II metabolism in pooled human liver S9 fraction (pHLS9) and HepaRG cells, and monooxygenases activity. Methoxycathinones exhibited lower PPB (~ 40-60%) compared to methylthiocathinones (~ 85%). Predominant phase I metabolic reactions included O-/S-demethylation and hydroxylation, with additional transformations such as N-dealkylation, N-oxidation, and oxo reduction. Phase II conjugation reactions, such as glucuronidation and sulfation, were observed post-demethylation. Overall, 42 and 45 metabolites were identified in pHLS9 and HepaRG systems, respectively, with metabolite number increasing alongside alkyl chain length and heterocyclic substitution. All compounds were substrates for multiple monooxygenases, suggesting a low risk for drug-drug interactions. Based on metabolic stability and abundance, parent compounds and O-/S-desmethyl and hydroxylated metabolites might be proposed as urinary screening targets in clinical and forensic toxicology, as well as doping control settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.